Activity of the immunologic doublet of lenalidomide plus obinutuzumab in relapsed follicular lymphoma: Results of a phase I/II study.

Nathan Fowler,Sattva S. Neelapu,Felipe Samaniego,Sheryl G. Forbes,Fredrick B. Hagemeister,Luis Fayad,Lei Feng,Francesco Turturro,Jason R. Westin,Janine Arafat,Eleanor Neal,Loretta J. Nastoupil

Activity of the immunologic doublet of lenalidomide plus obinutuzumab in relapsed follicular lymphoma: Results of a phase I/II study.

2017

Nathan Fowler
Sattva S. Neelapu
Felipe Samaniego
Sheryl G. Forbes
Fredrick B. Hagemeister
Luis Fayad
Lei Feng
Francesco Turturro
Jason R. Westin
Janine Arafat
Eleanor Neal
Loretta J. Nastoupil

7531Background: Relapsed follicular lymphoma (FL) remains a challenge and salvage regimens are associated with toxicity and limited control. Outcomes are linked to the immune microenvironment and l...

Keywords:

Obinutuzumab
Follicular lymphoma
Lenalidomide
Pathology
Cancer research
Medicine
Toxicity
immune microenvironment
phase i ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations